Xencor to Host Webcast to Discuss Results From the Phase 1 Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
Business Wire•19/10/2026•07:01 ET
0
Key Highlights
- ➤XmAb819 Phase 1 results will be presented at ESMO Congress 2026
- ➤Xencor plans a registration-enabling XmAb819 monotherapy study in 2027
- ➤Intravenous expansion cohorts support dose selection for planned Phase 3 study
- ➤Subcutaneous XmAb819 dose escalation in advanced ccRCC remains ongoing
- ➤ENPP3+ colorectal, lung and papillary renal cancer sub-study opened in Q2 2026
Expert Statements
Sumanta Pal, Professor and Vice Chair of Academic Affairs, City of Hope Comprehensive Cancer Center
“Phase 1 results of XmAb819, a novel ENPP3 x CD3 bispecific, in advanced clear cell renal cell carcinoma (ccRCC)”
Xencor to Host Webcast to Discuss Results From the Phase 1 Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, will host a webcast on Monday, October 26 at 7:00 a.m. EDT (4:00 a.m. PDT) to discuss results from the Phase 1 Study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in development for patients with advanced clear cell renal cell carcinoma (ccRCC).
Get started
Create a free account to read the full story.